Drug · Small Molecule

Vincristine

CI-DRUG-00000638Explore in graph →NCIt C933 CHEMBL90555 CIViC Approved

Regulatory

Approvals (8)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory8 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as VINCRISTINE SULFATE INJECTION USP (DIN 02183013) under ATC L01CA02 VINCRISTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 7, 1997	health-canada-dpd
CA Health Canada	—	Marketed in Canada as VINCRISTINE SULFATE INJECTION (DIN 02143305) under ATC L01CA02 VINCRISTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1995	health-canada-dpd
CA Health Canada	—	Marketed in Canada as VINCRISTINE SULFATE INJ 5MG/VIAL USP (DIN 00690317) under ATC L01CA02 VINCRISTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 15 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	196	86	261	862	8	CA, US	Apr 19, 1988	1977-09
Non-Hodgkin Lymphoma	Phase4	Phase 4	85	36	63	244	0	—	—	1993-03
Leukemia	Phase4	Phase 4	55	28	56	228	0	—	—	1990-01
Malignant Liver Neoplasm	Phase4	Phase 4	2	0	4	8	0	—

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 Fusion1
Dasatinib + Dexamethasone

Clinical trials

Trials with this intervention (870)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 870 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	active not recruiting	Phase 2	75	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT05600686	Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Molecule

Record

Kind: Small Molecule
Mechanism: Tubulin inhibitor
Targets: 15 genes
UNII: T5IRO3534A
Aliases: 22-Oxovincaleukoblastine, LCR, Leucristine, LEUROCRISTINE, Oncotcs, ONCOVIN, Tecnocris, VCR, Vincaleukoblastine, 22-oxo-, Vincristin, Vincristina, Vincristine, Vincristine Sulfate, VINCRISTINE SULFATE, Vincrystine, Vinkristin

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (15)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01CA02	VINCRISTINE
DIN (Health Canada)	00611182	ONCOVIN SOLUTION 1MG/ML
DIN (Health Canada)

NF1 G629R + NF1 Splice Site (c.205-1G>C)2
Carboplatin + Selumetinib + Trametinib + VincristineSubstitutes	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID12271 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic
〃	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	2	rejected	EID12359 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic